Uncategorized
Biotech stocks plunge and industry figures left to wonder after Prasad’s FDA appointment
United States Food and Drug Administration, Industry, Prasad, Appointments, stocks, Cell Therapy, Market, figures
Protect Your Trial Data: Endpoint, Imaging, and Safety Review
Clinical Trials, Diagnostic Imaging, Security – service, End Point, safety review, General Data Protection Regulation, Biomechanical compliance, CTMS, Encryption
RFK Jr. claims placebo-controlled vaccine trials are’radical departure’ from past. Experts disagree
Vaccines, placebo-controlled trials, CHARGE Syndrome, experts, Effectiveness, RFK Jr., Policy, Approved, HHS
NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader
Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases
Trumps US Manufacturing Push, New Vaccine Policy, Novos Weight Loss Pill up for FDA Review
Policy, trade deficits, Vaccines, United States Food and Drug Administration
Amid Trumps Trade War, Some Drugmakers Stockpile Products in U.S.
United States, Import, trade deficit
Beacon’s rare eye disease gene therapy signals vision function improvements in early phase 2 data
XLRP, gene therapy, laru-zova, visual function, rare eye disease, Phase 2 trial, DAWN trial, vision improvement, low light vision
Aldeyra hopes new data for dry-eye disease drug will satisfy FDA
United States Food and Drug Administration, Aldeyra, reproxalap, Approved, Dry Eye Syndromes, Clinical Trials, New Drug Application
Brian Armstrongs NewLimit raises a $130M Series B, laying out road map for anti-aging drugs
NewLimit, Brian Armstrong, Coinbase CEO, anti-aging drugs, epigenetic reprogramming, Series B funding, Kleiner Perkins, genetic cell programming, healthy lifespan extension